02026nas a2200241   4500000000100000008004100001653003900042653001600081653001200097653003500109100001700144700001200161700001400173700001000187700002000197700001600217700001400233700001700247245019100264856026000455520105500715022001401770       2019                            d10aNeglected tropical diseases (NTDs)10aElimination10aControl10amass drug administration (MDA)1 aWainwright E1 aEvans D1 aRotondo L1 aPou B1 aYevstigneyeva V1 aZoerhoff KL1 aOttesen E1 aReithinger R00aThe Elimination of Neglected Tropical Diseases (NTDs): A Case Study Exemplifying How Foreign Assistance Funding Can Be Catalytic in Reducing the Burden of Major Global Health Conditions.  uhttps://watermark.silverchair.com/ciz742.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAk8wggJLBgkqhkiG9w0BBwagggI8MIICOAIBADCCAjEGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMGTGf5EsPmQCNnb4wAgEQgIICAqQPZQQhOSJDWyAVXpMIgDtpABlEXS1r4WdnTaQlpAoIsLMT3 a<p>In 2006, following direct advocacy and published rationale, the U.S. Agency for International Development (USAID) established a neglected tropical disease (NTD) program to support the scale-up of integrated platforms targeting the elimination and control of five NTDs-lymphatic filariasis, trachoma, onchocerciasis, schistosomiasis and soil-transmitted helminthiasis. By 2017, a cumulative total of over 2.3 billion NTD treatments had been delivered to at-risk populations in 25 countries, leveraging $19 billion in donated drugs - approximately $26 dollars in donated medicine per $1 spent by USAID. As a result, most of the supported countries are on track to achieve their elimination goals (for lymphatic filariasis and trachoma) by 2020 or 2021 and their control goals soon thereafter. Though 'small' when compared to other global health initiatives, this investment proved to be catalytic-and indeed highlights how foreign assistance funding can be transformative-for reducing the burden of major global health conditions such as NTDs.</p>
  a1537-6591